CORRECTIONS

Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort

In the article “Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort” by Barber et al., the first sentence in the Methods section should denote this study as providing Class III evidence. The authors regret the error.

Reference

Leisure Activity Participation and Risk of Dementia
An 18-Year Follow-up of the Whitehall II Study

In the article “Leisure Activity Participation and Risk of Dementia: An 18-Year Follow-up of the Whitehall II Study” by Sommerlad et al., the second sentence of the Results section should read “During 147,774 person-years at risk, 360 incident dementia cases were recorded (incidence 2.4 per 1,000 person-years).” The short version of the article, published October 28, 2020, should also have stated “incidence 2.4 per 1,000 person-years.” The authors regret the error.

Reference

RETRACTION

An Alternative to Vitamin D Supplementation to Prevent Fractures in Patients With MS

The Editors retract the article “An Alternative to Vitamin D Supplementation to Prevent Fractures in Patients With MS.” We previously published an Expression of Concern about this Letter to the Editor along with several other articles by Y. Sato and others. Since then, the other articles in the Expression of Concern have been retracted.

The Letter to the Editor is strongly reliant on several of its references also authored by Y. Sato. We have learned that references 2, 4, 5, 6, and 7 in the Letter have been retracted by other journals and therefore retract this Letter.

References
2. Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease [Expression of Concern]. Neurology 2018;90:e627.
Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort

*Neurology* 2021;96;828
DOI 10.1212/WNL.0000000000009542

This information is current as of April 26, 2021

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/96/17/828.1.full">http://n.neurology.org/content/96/17/828.1.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 1 articles, 1 of which you can access for free at: <a href="http://n.neurology.org/content/96/17/828.1.full#ref-list-1">http://n.neurology.org/content/96/17/828.1.full#ref-list-1</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>